As of June 30, 2026, OncoTherapy Science, Inc. carries a market capitalization of 40.82M, placing it among publicly traded companies globally. Its enterprise value stands at 28.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 40.82M |
| Enterprise Value | 28.30M |
OncoTherapy Science, Inc.'s next confirmed earnings release is scheduled for January 29, 2027.
| Earnings Date | 1/29/2027 |
As of June 30, 2026, OncoTherapy Science, Inc. has 408.24M shares outstanding.
| Shares Outstanding | 408.24M |
These figures are as of June 30, 2026. The price-to-sales ratio is 8.73, and the price-to-book ratio stands at 3.23.
| PS Ratio | 8.73 |
| PB Ratio | 3.23 |
| P/TBV Ratio | 3.23 |
These figures are as of June 30, 2026. The EV/Sales ratio of 6.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 28.30M versus a market cap of 40.82M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 6.76 |
As of June 30, 2026, OncoTherapy Science, Inc. maintains a current ratio of 11.81, meaning it holds 11.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.81 |
| Quick Ratio | 10.72 |
| Interest Coverage | -603.81 |
Over the twelve months ended June 30, 2026, OncoTherapy Science, Inc. posted a negative return on equity (ROE) of -51.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -42.73, reflecting losses generated across the asset base. The company generates approximately 90,062.85 in revenue per employee across its workforce of 46.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.36 indicates how many times OncoTherapy Science, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -51.62 |
| Return on Assets (ROA) | -42.73 |
| Revenue Per Employee | 90,062.85 |
| Employee Count | 46.50 |
| Inventory Turnover | 7.36 |
Over the twelve months ended June 30, 2026, OncoTherapy Science, Inc. recorded 5,814.98 in income tax expense. The company reported a pretax loss of -4.75M and -4.77M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 5,814.98 |
As of the close on November 17, 2026, OncoTherapy Science, Inc.'s stock has declined approximately 27.50% over the past 52 weeks. The 50-day moving average sits at 0.11, while the 200-day moving average is 0.11.
| 52-Week Price Change | -27.50% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.11 |
Over the twelve months ended June 30, 2026, OncoTherapy Science, Inc. generated 4.19M in revenue and converted that into -4.77M in net income, yielding earnings per share of -0.01. EBITDA reached -4.26M, while operating income came in at -4.26M.
| Revenue | 4.19M |
| Gross Profit | 91,828.24 |
| Operating Income | -4.26M |
| Pretax Income | -4.75M |
| Net Income | -4.77M |
| EBITDA | -4.26M |
| EBIT | -4.26M |
| Earnings Per Share (EPS) | -0.01 |
These figures are as of June 30, 2026. Total book value stands at 12.64M, with working capital of 12.63M providing operational flexibility.
| Cash & Cash Equivalents | 12.53M |
| Net Debt | -12.53M |
| Equity (Book Value) | 12.64M |
| Book Value Per Share | 0.03 |
| Working Capital | 12.63M |
Over the twelve months ended June 30, 2026, OncoTherapy Science, Inc. posted a gross margin of 2.19, reflecting its pricing power and cost economics. The operating margin of -101.77 and net profit margin of -113.81 provide insight into operational efficiency.
| Gross Margin | 2.19 |
| Operating Margin | -101.77 |
| Pretax Margin | -113.53 |
| Profit Margin | -113.81 |
| EBITDA Margin | -101.77 |
OncoTherapy Science, Inc.'s most recent stock split took place on September 26, 2013 with a 1:500 split ratio.
| Last Split Date | 9/26/2013 |
| Split Ratio | 1:500 |
As of June 30, 2026, OncoTherapy Science, Inc. has an Altman Z-Score of 2.51, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.51 |
Already premium?